Extension of Post Importation Testing Exemptions

22 December 2020 Post Importation Testing Exemptions (PITE) granted due to COVID-19 pandemic Post importation testing exemption approvals granted since March 2020 due to the Covid-19 pandemic, are extended to 30 April 2021 without further need of an application thereof. The initial approval date was extended to...

20 August 2026 The South African Health Products Regulatory Authority (SAHPRA) wishes to remind healthcare professionals of the risk of angioedema during treatment with angiotensin-converting enzyme (ACE) inhibitors (e.g. captopril, enalapril, lisinopril, perindopril, quinapril, ramipril, trandolapril). Healthcare professionals are reminded that ACE inhibitor treatment should be...

Pretoria, 16 August 2026 – The South African Health Products Regulatory Authority (SAHPRA) has initiated the recall of four batches of Enalapril 10mg Arya, a medicine commonly used to treat high blood pressure (hypertension), following the identification of out-of-specification results during post-marketing surveillance inspections. The recall...

Pretoria, 08 July 2026 – The South African Pharmacy Council (SAPC), Health Professions Council of South Africa (HPCSA) and the South African Health Products Regulatory Authority (SAHPRA) hereby warn the public, pharmacies and dispensing medical practitioners against any continued use, prescription and/or dispensing of iDEXIS...

Pretoria, 23 May 2026 – The South African Health Products Regulatory Authority (SAHPRA), in collaboration with the South African Pharmacy Council (SAPC), has intensified enforcement action against the unlawful manufacturing and distribution of unregistered GLP-1 and GIP medicines containing either Semaglutide, Tirzepatide, or a combination...